- The FDA's recent roadmap aims to reduce animal testing in drug development, promoting alternatives like organoids and computer simulations.
- This shift is expected to impact companies reliant on animal models, particularly those involved in non-clinical safety evaluations, as they adapt to new technologies.
- While the transition may be gradual, the industry is increasingly investing in innovative solutions, indicating a long-term trend towards minimizing animal use in research.
